Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

Less than two years af­ter Take­da inked a col­lab­o­ra­tion with Po­sei­da Ther­a­peu­tics to de­vel­op six liv­er-di­rect­ed and hematopoi­et­ic stem cell-di­rect­ed in vi­vo gene ther­a­pies, Take­da will end the part­ner­ship on Ju­ly 30, the com­pa­ny con­firmed to End­points News.

The breakup is not un­ex­pect­ed, com­ing on the heels of Take­da’s April an­nounce­ment that it planned to stop dis­cov­ery and pre­clin­i­cal work in AAV gene ther­a­py, as well as re­search and pre­clin­i­cal work on rare hema­tol­ogy. A rep­re­sen­ta­tive for Take­da con­firmed that the part­ner­ship end­ed be­cause of the com­pa­ny’s de­ci­sion to stop that work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA